Evotec SE header image

Evotec SE

EVO

Equity

ISIN null / Valor 3979578

NASDAQ (2026-02-27)
USD 3.40-0.29%

Evotec SE
UMushroom community rating:

star star star star star
4.00 1 votes No rating yet
NegativeNeutralPositive

About company

Evotec SE is a global platform company focused on discovering and developing highly effective therapeutics in various therapeutic areas such as neurology, oncology, metabolic, and infectious diseases. The company leverages its data-driven multimodality platform and innovative technologies to create a world-leading pipeline of proprietary and co-owned R&D projects. With strategic partnerships with top pharmaceutical companies, biotechnology firms, academic institutions, and other healthcare stakeholders, Evotec aims to make its pharmaceutical products globally available to patients in need. Operating globally with over 5,000 employees across 17 sites in six countries, Evotec is committed to accelerating innovations and creating strategic collaborations to advance drug discovery projects and assets.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-22.6%1Y
-63.9%3Y
-82.4%5Y

Performance

56.9%1Y
85.0%3Y
75.9%5Y

Volatility

Market cap

604 M

Market cap (USD)

Daily traded volume (Shares)

49,811

Daily traded volume (Shares)

1 day high/low

4.53 / 4.28

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

1 votes
Performance:
starstarstarstarstar
4.00
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
4.00
Thomas Bühler
Switzerland, 24 Apr 2025
star star star star star
Nicht schlecht

EQUITIES OF THE SAME SECTOR

Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc Ultragenyx Pharmaceutical Inc Valor: 22860122
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.52%USD 23.39
Cencora Inc
Cencora Inc Cencora Inc Valor: 1212868
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.50%USD 372.14
Resmed Inc
Resmed Inc Resmed Inc Valor: 321632
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.31%USD 256.26
Indivior PLC
Indivior PLC Indivior PLC Valor: 121550831
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.45%GBP 24.34
Alkermes PLC
Alkermes PLC Alkermes PLC Valor: 13920929
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.05%USD 30.10
PTC Therapeutics Inc
PTC Therapeutics Inc PTC Therapeutics Inc Valor: 2515234
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.13%USD 68.19
National Vision Holdings Inc
National Vision Holdings Inc National Vision Holdings Inc Valor: 38523646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.06%USD 26.97
BioArctic AB
BioArctic AB BioArctic AB Valor: 38514501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.19%SEK 308.80
AbCellera Biologics Inc
AbCellera Biologics Inc AbCellera Biologics Inc Valor: 58489933
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.56%USD 3.61
Spire Healthcare Group PLC
Spire Healthcare Group PLC Spire Healthcare Group PLC Valor: 24881418
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.25%GBP 2.03